Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00409994

Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer

A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study

Sponsor: Academisch Ziekenhuis Maastricht

Conditions Rectum Cancer

Interventions Rapamycin

Updated 7 times since 2017 Last updated: Mar 14, 2019 Started: Sep 30, 2006 Primary completion: Aug 3, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00409994, this PHASE1/PHASE2 trial focuses on Rectum Cancer and remains completed. Sponsored by Academisch Ziekenhuis Maastricht, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Academisch Ziekenhuis Maastricht
Maastricht Radiation Oncology

Data source: Maastricht Radiation Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Maastricht, Netherlands